Morgan Stanley analyst Sarita Kapila lowered the firm’s price target on Argenx (ARGX) to EUR 650 from EUR 715 and keeps an Overweight rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Halozyme says Argenx received EU approval for Vyvgart with Enhanze for CIDP
- Argenx announces European Commission approval of VYVGART subcutaneous injection
- Promising Clinical Trial Results and Strategic Pipeline Development Position Argenx Se as a Strong Investment Prospect
- Argenx SE Reports Promising Phase 2 Results for Efgartigimod in Autoimmune Diseases
- Argenx presents new Efgartigimod data at EULAR 2025
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue